Infection associated with CDK4/6 inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system database

IntroductionCyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are first-line treatments for hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer. With their increasing clinical use, infection-related adverse events (AEs) associated with CDK4/6 inhibitors have b...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Jinhua Chen, Linlin Tang, Wenping Song, Cuicui Sun, Wenzhou Zhang
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Frontiers Media S.A. 2024-07-01
Σειρά:	Frontiers in Pharmacology
Θέματα:	CDK4/6 inhibitor FAERS infection adverse events ribociclib
Διαθέσιμο Online:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1371346/full
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!